SIRT3 and metabolic dysfunction-associated steatotic liver disease: Recent report emphasized that pharmacological activation of the SIRT3/ACSF3 pathway was an effective approach to alleviate NAFLD and protocatechuic acid was a novel candidate therapy for non-alcoholic fatty liver disease [20].